Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124241 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00124241 is a Phase 2 study that has completed, run by Novartis.
The verdict
NCT00124241, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepatitis B.
Interventions
- DRUG lamivudine
- DRUG telbivudine
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00124241
The ClinicalTrials.gov registry entry for NCT00124241 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lamivudine is the first listed.
NCT00124241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00124241 about?
NCT00124241 is a clinical study titled "An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B". This is an extension study for patients who have previously completed Idenix Study NV-02B-003. This study is being conducted to compare the safety and effectiveness of treatment beyond 1 year of telbivudine and telbivudine combined with lamivudine, a drug currently approved for the treatment of hepa...
What is the current status of trial NCT00124241?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00124241?
The interventions under investigation include: lamivudine (DRUG), telbivudine (DRUG).
Who is sponsoring clinical trial NCT00124241?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.